Doctor Corina Becker
Bayer AG, Wuppertal (Germany)
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Event: ESC Congress 2020
Topic: Cardiovascular Pharmacotherapy
Session: Pharmacology and Pharmacotherapy ePosters
Pharmacodynamic interaction study of a long-acting nitrate co-administered with vericiguat in patients with stable coronary artery disease
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy, Other
Session: Pharmacology and Pharmacotherapy
Pharmacodynamic and pharmacokinetic interaction profile of vericiguat
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy, Other
Session: Pharmacology and Pharmacotherapy
Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects
Event: Heart Failure 2019
Topic: Cardiovascular Pharmacotherapy, Other
Session: Pharmacology and Pharmacotherapy
ESC 365 is supported by
